NICE recommends Akcea’s Tegsedi for rare, life-threatening progressive disease

April 17, 2019
Research and Development, Sales and Marketing Akcea, NHS, NICE, Tegsedi, UK

Akcea Therapeutics has shared the news that Tegsedi (inotersen), its antisense oligonucleotide (ASO) inhibitor of human transthyretin (TTR) production, has …

chinese_flag_beijing_-_img_1104

China introduces new laws to ensure steady supply of drugs

April 17, 2019
Research and Development China, National Health Commission, laws, markets, pharma, regulation

China’s National Health Commission (NHC) has said it will monitor the country’s drugs market more closely in order to ensure …

gsk_ulverston_plant_impression

GSK to make redundancies at plant in Stevenage

April 17, 2019
Research and Development GSK, GlaxoSmithKline, R&D, redundancies, stevenage

GlaxoSmithKline are set to make redundancies at their site in Stevenage. The move comes as the firm takes “a new …

credit_-_daniel_leal-olivas-afp

Use of Genzyme’s MS drug Lemtrada restricted under ongoing EMA safety review

April 16, 2019
Manufacturing and Production, Sales and Marketing EMA, Genzyme, Lemtrada, multiple sclerosis, pharma

The EMA has launched a review into Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab) after reports emerged of treatment-related safety issues …

genentech_web

Genentech employee awarded $250,000 over racial discrimination case

April 16, 2019
Manufacturing and Production Genentech, discrimination, pharma, racial discrimination, racism

A US jury has awarded a former Genentech employee nearly $250,000 after the black worker was fired from the firm …

andrew_long

Insys Therapeutics names current CFO Andrew Long as company’s new CEO

April 16, 2019
Manufacturing and Production CEO, Insys Therapeutics, Subsys, appointments, cfo, pharma

Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s new CEO. The opioid drugmaker …

janssen_latest_logo_on_sign

Janssen’s Invokana combo smashes primary and secondary endpoints in chronic kidney disease

April 16, 2019
Manufacturing and Production, Research and Development Janssen, cardiovascular, chronic kidney disease, diabetes, invokana, pharma

Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …

Half of patients have sub-optimal response to statins, research shows

April 16, 2019
Manufacturing and Production NHS, NICE, NICE guidelines, cholesterol, health, statins

Around half of patients who are prescribed statins do not see their cholesterol drop to desired levels within two years, …

Pfizer unveils new Phase 2 data on 20-valent pneumococcal conjugate vaccine

April 15, 2019
Research and Development, Sales and Marketing Pfizer, Streptococcus pneumoniae, Vaccine, pharma

Pfizer has revealed new Phase 2 data on its 20-valent pneumococcal conjugate vaccine candidate, known as PF-06482077 (20vPnC), detailing the …

Bowel cancers adjust themselves to hide from immunotherapies

April 15, 2019
Sales and Marketing CEA, Cancer, bowel cancer, immunotherapy, oncology, tumour

Bowel cancers can avoid being caught by immunotherapy by ‘switching off’ a molecule on the surface of cells that is …

Doctors treat porphyria using innovative gene silencing drug

April 15, 2019
Sales and Marketing RNA, gene silencing, genetics, givosiran, health, porphyria

Doctors have successfully treated porphyria using an innovative ‘gene-silencing’ drug. Speaking to the BBC, Professor David Rees, from King’s College …

janssen_latest_logo_on_sign_closer

Janssen’s Balversa becomes first FDA-approved FGFR kinase inhibitor for advanced bladder cancer

April 15, 2019
Sales and Marketing Balversa, Cancer, FDA, Janssen, bladder cancer, pharma

Janssen’s Balversa (erdafitinib) has become the first FDA-approved fibroblast growth factor receptor (FGFR) kinase inhibitor after the US agency authorised …

about2medical

Medical cannabis: A green light for patients in need?

April 15, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Insider Interview, Medical marijuana, cannabis, feature, pharma

Spinnaker Opportunities announced in February it had reached a preliminary agreement to acquire cannabis oil-focused research firm Kanabo Research and …

Clovis Oncology discontinue phase 2 bladder cancer trial

April 15, 2019
Sales and Marketing Cancer, Clovis Oncology, US, bladder cancer, metastatic bladder cancer

Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is …

Bayer VP elected to two of the firm’s executive committees

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, appointment

Dr Monika Lessl has been appointed to Bayer Foundations’ executive committee, selected by the German pharmaceutical firm’s Board of Management …

manabe

Daiichi Sankyo name current COO Sunao Manabe as firm’s new CEO

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Daiichi Sankyo have said Sunao Manabe, the company’s current COO will take over from George Nakayama as the firm’s new …

28246711066_52e38bc591_z

NHS Confederation chief says news of Brexit extension is a relief

April 12, 2019
EU, NHS, UK, brexit, health, medicine

Niall Dickson, the Chief Executive of the NHS Confederation, has said news of the decision to extend the Brexit deadline …

darren_cline

GW Pharma announce Darren Cline as company’s new Chief Commercial Officer

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

GW Pharmaceuticals have announced the appointment of Darren Cline as the company’s new US Chief Commercial Officer. Cline will lead …

merckwindow_web

FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer

April 12, 2019
Medical Communications, Research and Development Cancer, MSD, keytruda, lung cancer, non-small cell lung cancer, pharma

MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line …

janssen_latest_logo_on_sign_closer

Janssen’s Symtuza around 90% effective in achieving undetectable HIV-1 viral loads, when used immediately following diagnosis

April 12, 2019
Medical Communications HIV, Janssen, Symtuza, pharma

Janssen has lifted the curtain on data from the first Phase 3 trial investigating the efficacy of Symtuza (darunavir 800mg, …

The Gateway to Local Adoption Series

Latest content